News | April 17, 2026
NIFTY Pharma shows stable trend amid cautious market sentiment
Muted movement reflects consolidation phase as investors await earnings triggers
Muted movement reflects consolidation phase as investors await earnings triggers
New purpose-built AI model targets faster R&D cycles and deeper scientific insights across life sciences
Zero-observation outcomes strengthen global credibility and accelerate CDMO ambitions
The company reported net revenue of SEK 13.5 million for the full year 2025
This development signals a cleanup of Anlon’s borrowing profile and closure of legacy debt facilities
The grant backed by Novartis to strengthen academia-industry collaboration across all seven NIPERs
he innovation could pave the way for early and low-cost screening of smoking exposure and second-hand smoke biomarkers
The collaboration combines Alveus’ expertise in metabolic biology and therapeutic strategy with Aurigene’s integrated discovery capabilities
The CE Mark builds on the company’s ISO 13485 certification, further strengthening confidence in the platform's safety, quality and performance
The event marks a significant push into South Korea’s rapidly expanding bio-health ecosystem
Subscribe To Our Newsletter & Stay Updated
